ÁñÁ«¹ÙÍø
Back to

Dr Catherine Toong

Conjoint Lecturer
Medicine & Health
School of Clinical Medicine
Phone
87388363 (office), 98285113 (lab)
E-mail
catherine.toong@health.nsw.gov.au
Location
Immunology department, Liverpool hospital and NSW Health Pathology Liverpool
  • Journal articles | 2023
    Malik S; Toong C, 2023, 'Monoclonal antibody interference in electrophoresis', Pathology, 55, pp. 163 - 165,
    Journal articles | 2023
    Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg DR, 2023, 'Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses', Journal of Gastroenterology and Hepatology (Australia), 38, pp. 724 - 732,
    Journal articles | 2023
    Stoyanov A; Toong C; Kong Y; Chen R; Urriola N, 2023, 'Serum protein electrophoresis and rheumatoid factor analysis is an effective screening strategy for cryoglobulinaemia', Pathology, 55, pp. 391 - 396,
    Journal articles | 2022
    Liu Z; Julsgaard M; Zhu X; Martin J; Barclay ML; Cranswick N; Gibson PR; Gearry RB; Van Der Giessen J; Connor SJ; Rosella O; Grosen A; Toong C; Flanagan E; Wieringa JW; Janneke Van Der Woude C; Bell SJ; Kanis S; Fallingborg J; Hvas CL; Christensen LA; Connell WR; Brown SJ; Kjeldsen J; Wildt S; Svenningsen L; Sparrow MP; Walsh A; Radford-Smith G; Lawrance IC; Andrews JM; Ellard K, 2022, 'Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero: A Prospective Cohort Study in 107 Children', Journal of Crohn's and Colitis, 16, pp. 1835 - 1844,
    Journal articles | 2021
    Gu B; De Gregorio M; Pipicella JL; Vande Casteele N; Andrews JM; Begun J; Connell W; D'Souza B; Gholamrezaei A; Hart A; Liew D; Radford-Smith G; Rimola J; Sutherland T; Toong C; Woods R; Wu Y; Xuan W; Williams AJ; Ng W; Ding NS; Connor S, 2021, 'Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol', BMJ open, 11,
    Journal articles | 2021
    West TA; Sam M; Toong C, 2021, 'Comparison of three commercially available ELISA assays for anti-infliximab antibodies', Pathology, 53, pp. 508 - 514,
    Journal articles | 2021
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Williams AJ; Ng W; Connor S, 2021, 'Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings', Internal Medicine Journal, 51, pp. 739 - 745,
    Journal articles | 2021
    Yap JY; Moens L; Lin MW; Kane A; Kelleher A; Toong C; Wu KHC; Sewell WA; Phan TG; Hollway GE; Enthoven K; Gray PE; Casas-Martin J; Wouters C; De Somer L; Hershfield M; Bucciol G; Delafontaine S; Ma CS; Tangye SG; Meyts I, 2021, 'Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency', Journal of Clinical Immunology, 41, pp. 1915 - 1935,
    Journal articles | 2020
    Grey A; Sam M; Lehmann P; Tannous A; Papathomas E; Makris A; Natfaji A; Wong J; Toong C, 2020, 'Estimating urinary losses of rituximab in membranous nephropathy with nephrotic range proteinuria', Pathology, 52, pp. S41 - S41,
    Journal articles | 2020
    Sam MJ; Connor SJ; Ng WWS; Toong CML, 2020, 'Comparative Evaluation of 4 Commercially Available ELISA Kits for Measuring Adalimumab and Anti-adalimumab Antibodies', Therapeutic Drug Monitoring, 42, pp. 821 - 828,
    Journal articles | 2019
    Malik S; Toong C, 2019, 'Monoclonal antibody interference in serum electrophoresis', Pathology, 51, pp. S67 - S67,
    Journal articles | 2019
    West T; Sam M; Toong C, 2019, 'Comparison of three commercially-available elisa assays for anti-infliximab antibodies', Pathology, 51, pp. S132 - S133,
    Journal articles | 2018
    van der Poorten DK; McLeod D; Ahlenstiel G; Read S; Kwok A; Santhakumar C; Bassan M; Culican S; Campbell D; Wong SWJ; Evans L; Jideh B; Kane A; Katelaris CH; Keat K; Ko Y; Lee JA; Limaye S; Lin MW; Murad A; Rafferty M; Suan D; Swaminathan S; Riminton SD; Toong C; Berglund LJ, 2018, 'Gastric Cancer Screening in Common Variable Immunodeficiency', Journal of Clinical Immunology, 38, pp. 768 - 777,
    Journal articles | 2017
    Mitrev N; Vande Casteele N; Seow CH; Andrews JM; Connor SJ; Moore GT; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; van Langenberg D; Ward MG; Leong RW, 2017, 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases', Alimentary Pharmacology and Therapeutics, 46, pp. 1037 - 1053,
    Journal articles | 2017
    Toong CML; Lee MWM; Connor S; Ng W, 2017, 'Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits: author reply', Pathology, 49, pp. 334 - 335,
    Journal articles | 2016
    Lee MWM; Connor S; Ng W; Toong CML, 2016, 'Comparison of infliximab drug measurement across three commercially available ELISA kits', Pathology, 48, pp. 608 - 612,
    Journal articles | 2015
    Malkan A; Cappelen-Smith C; Beran R; Griffith N; Toong C; Wang MX; Cordato D, 2015, 'Anti-synthetase syndrome associated with anti PL-12 and anti-Signal recognition particle antibodies and a necrotizing auto-immune myositis', Journal of Clinical Neuroscience, 22, pp. 396 - 398,
    Journal articles | 2014
    Malkan A; Cordato D; Griffith N; Cappelen-Smith C; Toong C; Beran R, 2014, '10. Anti-synthetase syndrome associated with necrotizing myositis – Utility of myositis specific autoantibodies in predicting prognosis and choice of treatment', Clinical Neurophysiology, 125, pp. e4 - e4,
    Journal articles | 2012
    Barker R; Lehmann P; O’Neill S; Toong C, 2012, 'Phar lap and the filly: validating the anti-DSDNA-NCX IgG ELISA', Pathology, 44, pp. S69 - S69,
    Journal articles | 2012
    Toong C, 2012, 'Use of cardiac MR imaging to evaluate the presence of myocarditis in autoimmune myositis: three cases', Rheumatology International, 32, pp. 779 - 782,
    Journal articles | 2011
    Toong C; Adelstein S; Phan TG, 2011, 'Clearing the complexity: immune complexes and their treatment in lupus nephritis', International Journal of Nephrology and Renovascular Disease, 4, pp. 17 - 28,
    Journal articles | 2009
    Toong C; Puranik R; Adelstein S, 2009, 'Use of Cardiac MR Imaging to Evaluate the Presence of Myocarditis in Autoimmune Myositis: 3 Cases', Heart, Lung and Circulation, 18, pp. S59 - S59,
    Journal articles | 2007
    Toong C; Quin J, 2007, 'Investigation of the patient with suspected allergy', Medicine Today, 8, pp. 49 - 56
  • Conference Abstracts | 2022
    Hu H; Carr A; Deenick E; Phan TT; Kelleher A; Tong W; Moore J; Evans L; Toong C; Murad A; Kane A, 2022, 'PATIENT PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE IN AN AUSTRALIAN ADULT PRIMARY IMMUNODEFICIENCY COHORT', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 52, pp. 27 - 27,
    Conference Abstracts | 2022
    Srinivasan A; Cruz PD; Sam M; Toong C; Langenberg DRV, 2022, 'Mo1541: INFLIXIMAB DOSE INTENSIFICATION FOR SECONDARY LOSS OF RESPONSE IN IBD: UPFRONT INTENSIFICATION IS SIMILARLY EFFECTIVE TO DOSE INTERVAL SHORTENING WITH THE ADDED BENEFIT OF EARLY PREDICTORS OF RESPONSE', in Gastroenterology, Elsevier BV, Vol. 162, pp. S - 810,
    Conference Abstracts | 2022
    Srinivasan A; De Cruz P; Sam M; Toong C; Van Langenberg D, 2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 16, pp. I437 - I438,
    Conference Abstracts | 2022
    Srinivasan A; De Cruz P; Sam M; Toong C; Van Langenberg DR, 2022, 'INFLIXIMAB DOSE INTENSIFICATION FOR SECONDARY LOSS OF RESPONSE IN IBD: UPFRONT INTENSIFICATION IS SIMILARLY EFFECTIVE TO DOSE INTERVAL SHORTENING WITH THE ADDED BENEFIT OF EARLY PREDICTORS OF RESPONSE', in GASTROENTEROLOGY, W B SAUNDERS CO-ELSEVIER INC, CA, San Diego, Vol. 162, pp. S810 - S810, presented at Digestive Disease Week (DDW), CA, San Diego, 21 May 2022 - 24 May 2022,
    Conference Abstracts | 2022
    Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg D, 2022, 'P462 Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in Journal of Crohn's and Colitis, Oxford University Press (OUP), Vol. 16, pp. i437 - i438,
    Conference Abstracts | 2022
    Srinivasan A; De Cruz P; Sam M; Toong C; van Langenberg D, 2022, 'Upfront infliximab dose intensification for secondary loss of response in IBD: similar efficacy to dose interval shortening with the added advantage of early clinical and pharmacokinetic predictors of response', in JOURNAL OF CROHNS & COLITIS, OXFORD UNIV PRESS, Vol. 16, pp. I437 - I438,
    Conference Abstracts | 2022
    Stoyanov A; Toong C; Kong Y; Urriola N, 2022, 'Serum protein electrophoresis and rheumatoid factor analysis as a screening strategy for cryoglobulinaemia', in Pathology, Elsevier BV, Vol. 54, pp. S82 - S82,
    Conference Abstracts | 2021
    Tong W; Loprete J; Richardson R; Kane A; Katelaris C; Post J; Wainstein B; Wong M; Campbell D; Swaminathan S; Suan D; Evans L; Law M; McMullan B; Murad A; Toong C; Torda A; Carr A, 2021, 'STANDARDISED TESTING AND COMMUNICATION INCREASE BETA-LACTAM ALLERGY DELABELLING EFFECTIVENESS: RESULTS OF 'DE-LABELLING PATIENTS WITH ANTIBIOTIC ALLERGY IN SYDNEY ADULT AND PAEDIATRIC HOSPITALS'', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 51, pp. 13 - 14,
    Conference Abstracts | 2020
    Loprete J; Richardson R; Kane A; Katelaris C; Post J; Wainstein B; Wong M; Campbell D; Evans L; Mcmullan B; Murad A; Toong C; Torda A; Carr A, 2020, 'De-labelling patients with antibiotic allergy in Sydney adult and paediatric hospitals-towards standardisation and improved patient outcomes', in ALLERGY, WILEY, ENGLAND, London, Vol. 75, pp. 216 - 216, presented at European-Academy-of-Allergology-and-Clinical-Immunology Digital Congress (EAACI), ENGLAND, London, 06 June 2020 - 08 June 2020,
    Conference Abstracts | 2019
    Loprete J; Richardson R; Kane A; Katelaris C; Post J; Wainstein B; Wong M; Campbell D; Evans L; McMullan B; Murad A; Toong C; Torda A; Carr A; Tong W, 2019, 'DE-LABELLING PATIENTS WITH ANTIBIOTIC ALLERGY IN SYDNEY ADULT AND PAEDIATRIC HOSPITALS- TOWARDS STANDARDISATION AND IMPROVED PATIENT OUTCOMES', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 49, pp. 15 - 15,
    Conference Abstracts | 2018
    Berglund LJ; McLeod D; Ahlenstiel G; Read S; Kwok A; Santhikumar C; Bassan M; Evans L; Kane A; Katelaris CH; Keat K; Ko Y; Lee JA; Limaye S; Lin MW; Murad A; Rafferty M; Suan D; Swaminathan S; Riminton DS; Toong C; van der Poorten DK, 2018, 'GASTRIC CANCER SCREENING IN COMMON VARIABLE IMMUNODEFICIENCY', in INTERNAL MEDICINE JOURNAL, WILEY, Vol. 48, pp. 27 - 27,
    Conference Papers | 2017
    Lin B; Wu Y; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Ng W; Connor S, 2017, 'Biological level testing in inflammatory bowel disease identifies inappropriate use of infliximab, with substantial associated cost savings', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 132 - 133,
    Conference Papers | 2017
    Mitrev N; Vande Casteele N; Seow C; Andrews JM; Connor SJ; Moore G; Barclay M; Begun J; Bryant R; Chan W; Corte C; Ghaly S; Lemberg DA; Kariyawasam V; Lewindon P; Martin J; Mountifield R; Radford-Smith G; Slobodian P; Sparrow M; Toong C; Van Langenberg D; Ward MG; Leong RW, 2017, 'Therapeutic drug monitoring-guided biological drug therapy in inflammatory bowel disease: Consensus statements of the Australian Inflammatory Bowel Disease Association (AIBDA) and Gastroenterological Society of Australia (GESA)', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 136 - 138,
    Conference Papers | 2017
    Wu Y; Lin B; Thilakanathan C; Lehmann P; Xuan W; Mohsen W; Toong C; Ng W; Connor S, 2017, 'Secondary loss of response is the most common indication for infliximab level testing in inflammatory bowel disease: The Australian experience', in JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, WILEY, pp. 153 - 154,
    Conference Papers | 2013
    Barker R; Toong C, 2013, 'AN AETIOLOGY FOR IgG4 RELATED DISEASE?', in INTERNAL MEDICINE JOURNAL, WILEY-BLACKWELL, pp. 22 - 22,
    Conference Presentations | 2013
    Urriola N; Toong C, 2013, 'A BRAF NEW WORLD', Vol. 43, pp. 25 - 25,